A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy

Michael W. Ruff, Elizabeth L. Siegler, Saad S. Kenderian

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Chimeric antigen receptor–engineered T (CAR-T) cell immunotherapy has been successful in treating many types of hematological malignancies. CAR-T therapy, however, has been associated with toxicities, including cytokine release syndrome (CRS) as well as immune effector cell–associated neurotoxicity syndrome (ICANS). ICANS presentation is variable, largely reversible, and manifests with encephalopathy and focal neurologic deficits. Treatment strategies largely are supportive. ICANS pathophysiology likely is related to that of CRS. Preclinical studies and clinical experience have shed light on the driving forces of ICANS and have yielded new strategies to mitigate ICANS occurrence.

Original languageEnglish (US)
Pages (from-to)953-963
Number of pages11
JournalNeurologic clinics
Volume38
Issue number4
DOIs
StatePublished - Nov 2020

Keywords

  • Axicabtagene ciloleucel
  • CAR-T
  • Chimeric antigen receptor
  • Neurotoxicity
  • Tisagenlecleucel

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy'. Together they form a unique fingerprint.

Cite this